Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for prostate cancer
|Recruiting||17777 A Randomized, double –blind, placebo –controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer. BAY 1841788/17777||Royal Adelaide Hospital|
|Not yet recruiting||3194007 ARAMIS A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer.||Ashford Cancer Centre Research|
|Recruiting||64091742PCR2001 (GALAHAD) A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies.||Ashford Cancer Centre Research|
|Recruiting||ANZUP1303 Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer||Ashford Cancer Centre Research|
|Not yet Recruiting||ARCHES astellas prostate. A Multinational, Phase 3, Randomized, Double-blind, Placebocontrolled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)||Flinders Medical Centre|
|Recruiting||CO39303 - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisolone/ Prednisolone, Relative To Placebo Plus Abiraterone Plus Prednisolone / Prednisolone In Adult Male Patients With Asymptomatic Or Midly Symptomatic, Previously Untreated, Metastatic-Castrate Resistant Prostate Cancer.||Ashford Cancer Centre Research|
|Recruiting||CO39385 - Imbassador 250: A phase III, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with enzalutamide versus enzalutamide alone in patients with metatstatic castration-resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen.||Ashford Cancer Centre Research|
|Recruiting||EMBARK Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy||Royal Adelaide Hospital|
|Recruiting||ENZARAD - Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localized, prostate cancer||Flinders Medical Centre|
|Recruiting||A Phase III, open-label, randomized study to assess the efficacy and safety of Olararib (Lynparza) vs Enzalutamide or Abiraterone Acetate in men with MCRPC who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations||Royal Adelaide Hospital|
|Not Yet Recruiting||proPSMA A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy||Royal Adelaide Hospital|
|Not yet Recruiting||TDM in Prostate Cancer Therapeutic Drug Monitoring of Docetaxel during treatment for men with Prostate Cancer||Flinders Medical Centre|
|Recruiting||VIPER A Phase I trial of Sodium Valproate/MetformIn Combination as neoadjuvant therapy for ProstatE canceR – VIPER 1 trial||Flinders Medical Centre|